"While NLT has yet to provide us with a copy of the complaint it filed against us, based on NLT's press release today, we believe that the allegations are frivolous and without merit. BIOLASE intends to defend the lawsuit vigorously, and will explore asserting appropriate claims against NLT," said BIOLASE CEO Jake St. Philip. "We cannot guarantee the safety, effectiveness, or regulatory compliance of any used BIOLASE laser sold or modified by third-parties, and we will continue to work hard to protect dentists and patients, which is of the utmost importance to us."
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, contact: David M. Mulder Chief Financial Officer of BIOLASE Technology, Inc. +1-949-361-1200 or Jill Bertotti Allen & Caron +1-949-474-4300
SOURCE: BIOLASE Technology, Inc.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index